Development of a PRAME pMHC targeted T cell engager for solid tumor therapy
Bispecific T cell engager (TCE) therapies have demonstrated transformative clinical success in the treatment of hematological cancers, but the lack of antigens that are sufficiently selective for malignant cells has hampered the success of TCEs in the solid-tumor space. To overcome the on-target, of...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Taylor & Francis Group
2025-12-01
|
| Серии: | mAbs |
| Предметы: | |
| Online-ссылка: | https://www.tandfonline.com/doi/10.1080/19420862.2025.2563773 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|